The Present and FutureJACC State-of-the-Art ReviewCardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review
JACC State-of-the-Art Review
Under an Elsevier user license
open archive
Central Illustration
Key Words
adipokines
adiposity
atherosclerosis
atrial fibrillation
cardiomyopathy
cardiovascular
chronic disease
dysglycemia
insulin resistance
obesity
type 2 diabetes
Abbreviations and Acronyms
ABCD
adiposity-based chronic disease
AF
atrial fibrillation
AGE
advanced glycation end-products
BMI
body mass index
BP
blood pressure
CHD
coronary heart disease
CMBCD
cardiometabolic-based chronic disease
CV
cardiovascular
CVD
cardiovascular disease
DBCD
dysglycemia-based chronic disease
FFA
free fatty acid(s)
HDL
high-density lipoprotein
HF
heart failure
HTN
hypertension
IL
interleukin
LDL
low-density lipoprotein
LDL-c
low-density lipoprotein cholesterol
LV
left ventricular
MetS
metabolic syndrome
NO
nitric oxide
T2D
type 2 diabetes
TNF
tumor necrosis factor
VLDL
very low-density lipoprotein
WC
waist circumference
WHtR
waist-to-height ratio
Cited by (0)
Dr. Mechanick has received honoraria for lectures from Abbott Nutrition International. Dr. Farkouh has received research grants from Amgen, Novartis, and Novo Nordisk. Dr. Newman has received research grants from the National Institutes of Health National Heart, Lung, and Blood Institute K23HL125991; and has received honoraria from Creative Educational Concepts. Dr. Garvey has served on ad hoc advisory boards for Sanofi, Novo Nordisk, Boehringer Ingelheim, Gilead, Amgen, BOYDSense, and the American Medical Group Association; and has conducted research sponsored by the University of Alabama at Birmingham funded by Sanofi, Merck/Pfizer, Novo Nordisk, AstraZeneca, and Lexicon.
© 2020 by the American College of Cardiology Foundation. Published by Elsevier.